Danish pharmaceutical giant Lundbeck, which is one of several companies fined by the European Commission after an industry-wide probe, is slamming the regulator for fining the company on what it deems unreasonable grounds. The Commission raided Lundbeck offices in 2005 and then fined the company for making anticompetitive agreements with other pharmaceutical companies that barred them from producing generic forms of ones of Lundbeck’s most popular drugs. While the company claims those agreements were legal, and that it had the right to make those contracts while key patent lawsuits were being decided, the European Commission is fighting pharmaceutical companies against such so-called pay-for-delay schemes. Lundbeck is currently speaking out against the regulator for fining the company and modifying its accusations after the company sent a statement of objections concerning the Commission’s ruling.
Featured News
Trump’s Defamation Case Against New York Times Advances in Federal Court
Nov 19, 2026 by
CPI
Musk’s xAI Faces Skeptical US Judges Over California AI Disclosure Law
Nov 19, 2026 by
CPI
Italy Ends Vorwerk Antitrust Probe After Consumer Compensation Deal
Nov 19, 2026 by
CPI
Canada Wins Court Order to Advance Gap, Old Navy Advertising Probe
Nov 19, 2026 by
CPI
Russia Orders Major Retailers to Disclose Food Pricing Data in Antitrust Review
Nov 19, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Labor Market Collusion
Nov 19, 2026 by
CPI
From Price-Fixing to Wage-Fixing: Are Labor Markets the Next Frontier of Public and Private Competition Law Enforcement?
Nov 19, 2026 by
Giulia Rurali & Carsten Krüger
Damage Estimation and Labor Market Collusion
Nov 19, 2026 by
Louis D. Pape
Recent Developments of Labor Market Collusion in the EU: The Dialogue Between Delivery Hero and Tondela
Nov 19, 2026 by
Catarina Vieira Peres & Rita Ferreira Gomes
Enforcement in Labor Collusion and Monopsony: Trends and Challenges
Nov 19, 2026 by
Leyla Karakas & Anna Meyendorff